Volume 26 Issue 1, February 2021 Dave Pechter discusses the February SLAS Technology Special Collection AI in Process Automation with Guest Editor Cenk Undey (Amgen), which includes the following papers: Artificial Intelligence Effecting a Paradigm Shift in Drug Development by Masturah Bte Mohd Abdul Rashid Artificial Intelligence (AI) to the Rescue: Deploying Machine Learning to Bridge the Biorelevance Gap in Antioxidant Assaysby Sunday Olakunle Idowu and Amos Akintayo Fatokun Deep Learning and Computer Vision Strategies for Automated Gene Editing with a Single-Cell Elect ..read more

SLAS Discovery 25.10 December 2020Rob Howes discusses the paper "High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2" with authors Meredith Gardner (Scripps Research) and Michael Farzan (Scripps Research). This research is part of the December Special Issue, Drug Discovery Targeting COVID-19 with Associate Editor Tim Spicer ..read more

..read more

Volume 25 Issue 5, June 2020 Dave Pechter discusses with Varun Bhaskar Kothamachu, Ph.D. (Head of Product, Digi.Bio) & Sabrina Zaini (Head of Operations, Digi.Bio) their featured research article, "Role of Digital Microfluidics in Enabling Access to Laboratory Automation and Making Biology Programmable ..read more

SLAS Technology 25.4 August 2020 Dave Pechter discusses with Christian Heiss & Parastoo Azadi regarding the SLAS Technology Special Issue: Carbohydrate Structure Analysis: Methods and Applications ..read more

Volume 25 Issue 6, July 2020 Podcast Editor Rob Howes discusses the SLAS Discovery 2020 July Special Issue with Guest Editors Davide Gianni and Stuart Farrow. This Special Issue of SLAS Discovery presents the topic “Functional Genomics for Target Identification” and is focused on three strategic pillars that form the foundation of the functional genomics discipline. Articles span a variety of relevant topics, from the development of more translatable models of diseases to the creation of validated screening libraries, technologies and computational pipelines to perturb gene function and enable ..read more

Volume 25 Issue 5, June 2020 Podcast Editor Rob Howes discusses the SLAS Discovery 2020 June Special Collection with SLAS Discovery Editorial Board Member Joseph G. McGivern. To read the editorial by Joseph G. McGivern and Mei Ding, click here. This Special Collection of SLAS Discovery presents a special collection reflecting recent advances and continuing challenges in the development and application of assay technologies that are applicable to drug discovery for ion channel targets ..read more

Two articles are discussed: Traceable Impedance-Based Dispensing and Cloning of Living Single Cells: Single-cell cloning is essential in stem cell biology, cancer research, and biotechnology. Regulatory agencies now require an indisputable proof of clonality that current technologies do not readily provide. Here, we report a one-step cloning method using an engineered pipet combined with an impedance-based sensing tip. This technology permits the efficient and traceable isolation of living cells, stem cells, and cancer stem cells that can be individually expanded in culture and transplanted. I ..read more

Robert M. Campbell, Ph.D., is Senior Research Advisor at Eli Lilly and Company in Indianapolis, IN, where he heads the Cancer Cell Growth and Epigenetics Group. Dr. Campbell has served as Editor-in-Chief of SLAS Discovery for the past 12 years, where he has been a vital leader to grow the journal and share its important content. In this podcast, Dr. Campbell talks with our SLAS Discovery Podcast Editor Rob Howes, Ph.D. (AstraZeneca Gothenburg, Sweden) to discuss his work with the journal, as well as a little history about SLAS and the journal, and to make a call to authors and readers about up ..read more

The clinical team attending to a patient upon a diagnosis is faced with two main questions: what treatment, and at what dose? Clinical trials’ results provide the basis for guidance and support for official protocols that clinicians use to base their decisions upon. However, individuals rarely demonstrate the reported response from relevant clinical trials, often the average from a group representing a population or subpopulation. The decision complexity increases with combination treatments where drugs administered together can interact with each other, which is often the case. Additionally ..read more